{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:02:59Z","timestamp":1780473779368,"version":"3.54.1"},"reference-count":8,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2026.70593","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:46:10Z","timestamp":1777293970000},"source":"Crossref","is-referenced-by-count":0,"title":["A CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy"],"prefix":"10.4274","author":[{"given":"G\u00f6k\u00e7e Naz","family":"K\u00fc\u00e7\u00fckba\u015f \u00d6z\u00f6nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Terzi Demirsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Mehtap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Metli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2040620720966120","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"2020","unstructured":"1. Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol. 2020;11:2040620720966120.","journal-title":"Ther Adv Hematol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/10428194.2017.1347929","article-title":"Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment","volume":"59","author":"Chelysheva","year":"2018","unstructured":"2. Chelysheva E, Turkina A, Polushkina E, Shmakov R, Zeifman A, Aleshin S, Shokhin I, Guranda D, Oksenjuk O, Mordanov S, Kazakbaeva K, Chilov G. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leuk Lymphoma. 2018;59:733-738.","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","unstructured":"3. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6:e2014028.","DOI":"10.4084\/mjhid.2014.028"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/ejh.13215","article-title":"Risks and challenges of CML management during pregnancy: looking for a balanced decision","volume":"102","author":"Chelysheva","year":"2019","unstructured":"5. Chelysheva E, Turkina A. Risks and challenges of CML management during pregnancy: looking for a balanced decision. Eur J Haematol. 2019;102:378-379.","journal-title":"Eur J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clml.2025.07.017","article-title":"Management of chronic myeloid leukemia during pregnancy: review of evidence and treatment algorithm","volume":"26","author":"Haddad","year":"2026","unstructured":"6. Haddad FG, Croden J, Sasaki K, Issa GC, Pemmaraju N, Kantarjian H, Jabbour E. Management of chronic myeloid leukemia during pregnancy: review of evidence and treatment algorithm. Clin Lymphoma Myeloma Leuk. 2026;26:19-25.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Br\u00fcmmendorf TH. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol. 2020;9:IJH26.","DOI":"10.2217\/ijh-2020-0004"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jama.2015.7120","article-title":"Noninvasive prenatal testing and incidental detection of occult maternal malignancies","volume":"314","author":"Bianchi","year":"2015","unstructured":"8. Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, Garber JE, Wilkins-Haug L, Vora NL, Warsof S, Goldberg J, Ziainia T, Halks-Miller M. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA. 2015;314:162-169.","journal-title":"JAMA"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:19:03Z","timestamp":1780471143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z5\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-70593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":8,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2026.70593","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]}}}